Wyeth Gains Phase III Candidate For Treatment Of Opioid Side Effects From Progenics
This article was originally published in The Pink Sheet Daily
Executive Summary
The $60 mil. deal gives Wyeth rights to three different dosage forms of methylnaltrexone for a range of opioid-induced conditions.